-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
FACI Magnesium Stearate
F20180001533
A
about
FACI
Faci Asia Pacific Pte Ltd was established in 1999 and is located in Jurong Island, Singapore and is wholly owned by Faci SpA
The pharmaceutical excipients produced by the Singapore factory mainly include magnesium stearate, calcium stearate, sodium stearate, and zinc stearate
Product Regulatory Advantages
01100% plant origin
02Pharmaceuticalgrade, in line with national pharmacopoeia
Compliant with USP, EP, BP, JP, ChP
US FDA DMF No.
China CDE registration number F20180001533
03Completecertification
ISO, HACCP, Kosher, HALAL, RSPO
Production Process
It is produced by the international mainstream one-step reaction method.
Factors Affecting Formulations
01Relative content of stearic acid and palmitic acid
Pharmacopoeia: C18 > 40%, C16 + C18 >90%
High content of C18 - good lubrication effect - good flow of powder and good compressibility of tablet
The composition of stearic acid affects the crystal form of magnesium stearate
02Free fatty acid content
Pharmacopoeia: <0.
Adverse reactions with tablet formulation ingredients
Limits depend on process and formulation stability studies
03Unreacted MgO
The reaction process of magnesium salts may reduce the lubricating effect;
Hydrophobic, potentially affecting mobility
04 Bulk density
Differences in particle size and structure , as well as particle-particle interactions , determine differences in bulk density
Differences in bulk and compacted densities predict powder flowability
Affect tableting pressure
05Residual through 200 mesh sieve
Large particles reduce coating effectiveness
Large particles cause aggregation
06Appropriate particle size distribution range
Smaller particle size—larger specific surface area
But smaller particles require more coating, extending drug release time
Higher magnesium stearate content resulted in higher tablet friability
Narrower particle size distribution for smoother coating
Based on the characteristics of each component of the tablet, select the appropriate particle size distribution range
07Suitable specific surface area
Large specific surface area, more uniform coating and better fluidity
However, the larger the specific surface area, the lower the tablet hardness
Scan the code to get samples
Agency brand
JRS|EVONIK|MERCK
ACG|INGREDION
FACI|OMYA